Free Trial
NASDAQ:RLYB

Rallybio (RLYB) Stock Price, News & Analysis

Rallybio logo
$0.56 -0.03 (-5.00%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$0.57 +0.01 (+1.93%)
As of 08/28/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rallybio Stock (NASDAQ:RLYB)

Key Stats

Today's Range
$0.55
$0.60
50-Day Range
$0.31
$0.63
52-Week Range
$0.22
$1.24
Volume
263,543 shs
Average Volume
444,131 shs
Market Capitalization
$23.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Hold

Company Overview

Rallybio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

RLYB MarketRank™: 

Rallybio scored higher than 60% of companies evaluated by MarketBeat, and ranked 426th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rallybio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rallybio has received no research coverage in the past 90 days.

  • Read more about Rallybio's stock forecast and price target.
  • Earnings Growth

    Earnings for Rallybio are expected to grow in the coming year, from ($1.34) to ($1.09) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rallybio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rallybio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rallybio has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Rallybio's valuation and earnings.
  • Percentage of Shares Shorted

    6.57% of the float of Rallybio has been sold short.
  • Short Interest Ratio / Days to Cover

    Rallybio has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Rallybio has recently decreased by 31.82%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Rallybio does not currently pay a dividend.

  • Dividend Growth

    Rallybio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.57% of the float of Rallybio has been sold short.
  • Short Interest Ratio / Days to Cover

    Rallybio has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Rallybio has recently decreased by 31.82%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Rallybio has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Rallybio this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for RLYB on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rallybio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.70% of the stock of Rallybio is held by insiders.

  • Percentage Held by Institutions

    90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Rallybio's insider trading history.
Receive RLYB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RLYB Stock News Headlines

Rallybio (NASDAQ:RLYB) Upgraded by Wall Street Zen to Sell Rating
This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
TD Cowen Reaffirms Their Buy Rating on Rallybio (RLYB)
Evercore ISI Remains a Hold on Rallybio (RLYB)
See More Headlines

RLYB Stock Analysis - Frequently Asked Questions

Rallybio's stock was trading at $0.96 at the start of the year. Since then, RLYB shares have decreased by 41.6% and is now trading at $0.5602.

Rallybio Corporation (NASDAQ:RLYB) issued its earnings results on Thursday, August, 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The company earned $0.21 million during the quarter. Rallybio had a negative net margin of 5,473.33% and a negative trailing twelve-month return on equity of 71.66%.

Rallybio (RLYB) raised $80 million in an initial public offering on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share.

Top institutional investors of Rallybio include Aberdeen Group plc (3.83%) and Canaan Partners XI LLC (2.26%).
View institutional ownership trends
.

Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Plug Power (PLUG).

Company Calendar

Last Earnings
8/07/2025
Today
8/28/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RLYB
CIK
1739410
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+792.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.78 million
Net Margins
-5,473.33%
Pretax Margin
-5,218.27%
Return on Equity
-71.66%
Return on Assets
-65.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.98
Quick Ratio
9.98

Sales & Book Value

Annual Sales
$640 thousand
Price / Sales
36.58
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.10 per share
Price / Book
0.51

Miscellaneous

Outstanding Shares
41,790,000
Free Float
38,151,000
Market Cap
$23.41 million
Optionable
Not Optionable
Beta
-1.12
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:RLYB) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners